Hat Trick for Hypertension: Strategies to Improve Outcomes With Single-Pill Combinations

Program Description

Hypertension greatly increases the burden of stroke and other cardiovascular comorbidities, with approximately 60% of strokes attributable to poor blood pressure control. Traditional management is often hindered by therapeutic inertia and the significant burden of multi-pill regimens, which severely increases dosing complexity, reduces patient adherence, and delays the time to optimal blood pressure control. As new 2025 AHA/ACC guidelines underscore the need for early and aggressive combination therapy, this webinar provides pharmacists with a review of best practices to transition from traditional approaches to optimized single-pill combination (SPC) strategies. Patient selection criteria for escalating treatment from dual SPCs to the novel fixed-dose triple therapy with telmisartan, amlodipine, and indapamide will be examined, utilizing risk stratification tools and integrating superior efficacy data from phase 3 trials. This webinar will equip practicing pharmacists to identify patients with hypertension who might benefit from triple combination therapy initiation, focusing on those with specific comorbidities and elevated risk. Presented in conjunction with the National Community Pharmacists Association, the webinar will specifically equip practical skills for community and independent pharmacists to implement collaborative care, including patient counseling points on adherence, adverse effect management, and titration timelines for this advanced regimen, to seamlessly integrate these evidence-based protocols into their daily practice workflow and significantly improve blood pressure control and treatment adherence in high-risk patients.

Target audience: Ambulatory Care Pharmacist, Community Pharmacist, Retail Pharmacist

Type of activity: Application
Release date: December 24, 2025
Expiration date: December 24, 2026

Time to complete activity: 1.0 hours

Learner level: Foundational, Intermediate, Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Identify patients with hypertension with elevated cardiovascular risk who would benefit from early combination therapy based on blood pressure thresholds and comorbidities
2. Compare the efficacy, safety, and dosing of triple versus dual antihypertensive combination products using recent trial data
3. Apply pharmacist-led counseling and titration protocols to improve initiation, adherence, and persistence with fixed-dose combinations

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-424-H01-P. The activity is available for CE credit through December 24, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Faculty

Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Adam C Welch, PharmD, MBA, FAPhA; Macara Desai; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms